αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies Journal Article


Authors: De Witte, M. A.; Janssen, A.; Nijssen, K.; Karaiskaki, F.; Swanenberg, L.; van Rhenen, A.; Admiraal, R.; van der Wagen, L.; Minnema, M. C.; Petersen, E.; Raymakers, R. A. P.; Westinga, K.; Straetemans, T.; Halkes, C. J. M.; Boelens, J. J.; Kuball, J.
Article Title: αβ T-cell graft depletion for allogeneic HSCT in adults with hematological malignancies
Abstract: We conducted a multicenter prospective single-arm phase 1/2 study that assesses the outcome of ab T-cell depleted allogeneic hematopoietic stem cell transplantation (allo-HSCT) of peripheral blood derived stem cells from matched related, or unrelated donors (10/10 and 9/10) in adults, with the incidence of acute graft-versus-host disease (aGVHD) as the primary end point at day 100. Thirty-five adults (median age, 59; range, 19-69 years) were enrolled. Conditioning consisted of antithymocyte globulin, busulfan, and fludarabine, followed by 28 days of mycophenolic acid after allo-HSCT. The minimal follow-up time was 24 months. The median number of infused CD341 cells and ab T cells were 6.1 3 106 and 16.3 3 103 cells per kg, respectively. The cumulative incidence (CI) of aGVHD grades 2-4 and 3-4 at day 100 was 26% and 14%. One secondary graft failure was observed. A prophylactic donor lymphocyte infusion (DLI) (13 105 CD31 T cells per kg) was administered to 54% of the subjects, resulting in a CI of aGVHD grades 2-4 and 3-4 to 37% and 17% at 2 years. Immune monitoring revealed an early reconstitution of natural killer (NK) and gd T cells. Cytomegalovirus reactivation associated with expansion of memory-like NK cells. The CI of relapse was 29%, and the nonrelapse mortality 32% at 2 years. The 2-year CI of chronic GVHD (cGVHD) was 23%, of which 17% was moderate. We conclude that only 26% of patients developed aGVHD 2-4 after ab T-cell-depleted allo-HSCT within 100 days and was associated with a low incidence of cGVHD after 2 years. This trial was registered at www.trialregister.nl as #NL4767. © 2021 by The American Society of Hematology.
Journal Title: Blood Advances
Volume: 5
Issue: 1
ISSN: 2473-9529
Publisher: American Society of Hematology  
Date Published: 2021-01-12
Start Page: 240
End Page: 249
Language: English
DOI: 10.1182/bloodadvances.2020002444
PROVIDER: scopus
PMCID: PMC7805311
PUBMED: 33570642
DOI/URL:
Notes: Article -- Export Date: 1 February 2021 -- Source: Scopus
Altmetric
Citation Impact
MSK Authors
  1. Jaap Jan Boelens
    99 Boelens